+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer



A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer



European Urology 33(5): 447-456



Objectives: To evaluate the efficacy and tolerability of 'Casodex' monotherapy (150 mg daily) for metastatic and locally advanced prostate cancer. Methods: A total of 1,453 patients with either confirmed metastatic disease (M1), or T3/T4 non-metastatic disease with elevated prostate-specific antigen (M0) were recruited into one of two identical, multicentre, randomised studies to compare 'Casodex' 150 mg/day with castration. The protocols allowed for combined analysis.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 008068837

Download citation: RISBibTeXText

PMID: 9643663


Related references

A Randomised Comparison of ‘Casodex’ Tm (Bicalutamide) 150 mg Monotherapy versus Castration in the Treatment of Metastatic and Locally Advanced Prostate Cancer. European Urology 33(5): 447-456, 1998

A randomised comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology 28(3): 215-222, 1995

Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. Bju International 98(3): 563-572, 2006

Changes in prostate-specific antigen in casodex (bicalutamide) monotherapy in a dose 150 mg/day given to patients with locally advanced and/or advanced prostatic cancer. Urologiia 2001(4): 26-29, 2001

The AVOCAT study: Bicalutamide monotherapy versus combined bicalutamide plus dutasteride therapy for patients with locally advanced or metastatic carcinoma of the prostate-a long-term follow-up comparison and quality of life analysis. Springerplus 5: 653, 2016

Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. RadioTherapy and Oncology 76(1): 4-10, 2005

A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group study no. 6. European Urology 42(3): 204-211, 2002

Randomised study of Casodex 50 MG monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. The Scandinavian Casodex Cooperative Group. Scandinavian Journal of Urology and Nephrology 30(2): 93-98, 1996

Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 Years of followup. Journal of Urology 164(5): 1579-1582, 2000

Bicalutamide Monotherapy Compared with Castration in Patients with Nonmetastatic Locally Advanced Prostate Cancer: 6.3 Years of Follow-up. Prostate Journal 3(1): 42-43, 2001

Comparison of Casodex 150 mg monotherapy with castration in previously untreated non-metastatic prostate cancer Mature survival results. European Urology 37(Suppl 2): 128, 2000

Randomised study of Casodex 50 MG monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology & Nephrology 30(2): 93-98, 1996

Multicentre randomized trial comparing triptorelin medical castration versus surgical castration in the treatment of locally advanced or metastatic prostate cancer. Progres en Urologie 17(2): 235-239, 2007

Bicalutamide (Casodex) 150 mg as adjuvant to radiotherapy in localized or locally advanced prostate cancer. International Journal of Radiation Oncology*biology*physics 51(3-Supp-S1): 15-16, 2001

Casodex (Bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: Results from two multicenter randomized trials at a median follow-up of 4 years. Urology 51(3): 389-396, 1998